MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Interest Expense 2011-2025 | PCRX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -373 K | -186 K | -11.3 M | 31.8 M | 25.7 M | 23.6 M | 21.9 M | 18 M | 7.06 M | 7.72 M | 8.28 M | 7.25 M | 1.81 M | 4.78 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.8 M | -11.3 M | 10.4 M |
Quarterly Interest Expense Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -110 K | -10.7 M | 4.4 M | - | -122 K | -39 K | -159 K | - | -422 K | -269 K | 9.59 M | - | 9.86 M | 8.83 M | 10.2 M | - | 7.33 M | 7.02 M | 6.97 M | - | 7.13 M | 5.46 M | 6.02 M | - | 5.94 M | 5.88 M | 5.81 M | - | 5.64 M | 5.4 M | 5.16 M | - | 5.13 M | 5.23 M | 2.59 M | - | 1.6 M | 1.73 M | 1.87 M | - | 1.9 M | 1.94 M | 2 M | 8.28 M | 2.04 M | 2.08 M | 2.11 M | - | 1.89 M | 1.91 M | 1.52 M | - | 456 K | 494 K | 514 K | - | 910 K | 676 K | 2.48 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | -10.7 M | 3.35 M |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
1.12 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
2.24 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
87.9 M | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
500 K | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
127 K | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
21.3 M | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
27.4 K | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
-28 M | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
20 K | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
606 K | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
2.3 M | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
Solid Biosciences
SLDB
|
652 K | $ 5.75 | -2.04 % | $ 235 M | USA |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 4.34 | 6.91 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
-5.37 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
900 K | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
764 K | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.99 | -9.95 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
862 K | $ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
cbdMD
YCBD
|
-29.5 K | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
46.6 M | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
300 K | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
175 K | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
592 M | $ 11.68 | 0.29 % | $ 14.2 B | USA |